[Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Rinsho Shinkeigaku
; 59(8): 536-540, 2019 Aug 29.
Article
em Ja
| MEDLINE
| ID: mdl-31341130
ABSTRACT
A 42-year-old woman diagnosed with multiple sclerosis (MS) at the age of 37 was initially treated with interferon-ß IM. The frequency of clinical relapses was twice in 4 years. At the age of 41, due to difficulty in administering muscle injections, an oral medication fingolimod was started. However, it was discontinued after a month due to decreased lymphocyte count, following which natalizumab was administered. The number of relapses increased 3 times in eleven months, and the number of T2 lesions on the MRI increased from 12 to 23. Natalizumab was discontinued because the test for the anti-natalizumab antibody was positive. It was suspected that both, the rebound syndrome caused by fingolimod cessation and the drug neutralization by anti-natalizumab antibodies, were associated with the exacerbation of disease activity. Thus, careful attention should be paid to potential occurrence of these events post switching between disease-modifying drugs for treating MS with high activity.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Substituição de Medicamentos
/
Cloridrato de Fingolimode
/
Natalizumab
/
Fatores Imunológicos
/
Imunossupressores
/
Esclerose Múltipla
Limite:
Adult
/
Female
/
Humans
Idioma:
Ja
Ano de publicação:
2019
Tipo de documento:
Article